Abstract Body

Background

Clonal hematopoiesis (CH) is the presence of somatically mutated hemopoietic progenitor cells without overt signs of hematologic abnormalities. CH is an age-related phenomenon that is associated with increased mortality. High prevalence of CH has been separately described in cohorts of people with HIV (PWH) with varying CD4 T cell counts and in patients (pts) with cancer. In a recent cross-sectional analysis of PWH and solid organ cancer types, CH prevalence was 23%. We investigated the CH prevalence and methylation assessment among older PWH and Kaposi sarcoma (KS), a virus-associated malignancy, before and after KS-directed therapy.

Methods

Peripheral blood DNA was extracted from pts samples and used for CH detection and epigenetic methylation assessment. CH detection was performed using a custom Agilent SureSelectXTHS2 library preparation and target enrichment kit, which captured whole exons of 76 genes commonly mutated in CH and hematologic malignancies. Germline variant filtering included consideration of variant allele frequency (VAF) and recurrent presence in reference noncancer populations. The 850 K MethylationEPIC v1 BeadChip was used to capture genome-wide methylation status. DNA methylation–based biological age acceleration was calculated using epigenetic clocks including Hovarth, PhenoAge, Frailty, epiTOC, and DunedinPACE (estimates pace of aging).

Results

Seventeen men with HIV and KS with a median (med) age of 55 years (range: 52-67 years), med CD4 T cell count of 126 cells/µL and med HIV viral load <20 copies/ml were included. The med time from HIV diagnosis and KS diagnosis to CH analyses was 14.9 years and 1.8 years, respectively. CH was detected in 10 of 17 (59%) pts before KS-directed therapy; 6 pts (35%) harbored CH mutations with >2% VAF. Fourteen pts had data on CD4 T-cell count before KS-directed therapy; CH was detected in 43% of pts with low CD4 T cell counts (<200 cells/µl) as compared to 21% in pts with CD4 >200 cells/µl (p=0.60). The DunedinPACE epigenetic measure was significantly higher among pts with low CD4 T cell counts (Figure 1). All 7 pts who had CH present at baseline and received KS-directed therapy had CH detectable after treatment initiation as well. There were no changes in the epigenetic clock measurements between the two treatment timepoints.  

Conclusions

Among older PWH and KS, there was a high prevalence of CH and evidence of an association between low CD4 T cell counts and pace of aging in this population.